Retatrutide Research in the UAE — The Triple Agonist Peptide from ZPHC
The UAE has one of the highest rates of obesity and metabolic syndrome in the world, with research from the Ministry of Health estimating that over 35% of UAE adults are obese and a significant proportion living with type 2 diabetes or pre-diabetic conditions. It is no surprise then that metabolic peptide research is one of the fastest growing areas of scientific interest in the region.
Retatrutide — also known as LY3437943 and developed by Eli Lilly — is at the forefront of this research wave. It is a triple agonist peptide that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple mechanism is what sets it apart from earlier generation compounds and has made it one of the most discussed peptides in metabolic research globally.
At Dxbpeptides.ae, we supply Retatrutide from ZPHC Pharma in multiple kit sizes, with 1-2 day delivery across the UAE and cash on delivery available.
How Retatrutide Works — The Triple Receptor Mechanism
Understanding why Retatrutide has attracted such intense research interest requires a brief explanation of the three receptor pathways it targets.
GLP-1 Receptor Agonism
The GLP-1 receptor is the same target as drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro). Activation of this receptor in research models has been associated with:
- Reduced appetite and food intake
- Slowed gastric emptying
- Improved insulin secretion in response to glucose
- Reduced glucagon secretion, lowering blood sugar levels
- Cardiovascular protective effects in preclinical models
GLP-1 agonism is now well established in metabolic research, with multiple approved pharmaceutical treatments based on this mechanism. Retatrutide builds on this foundation.
GIP Receptor Agonism
The GIP receptor is the second target, the same one activated by tirzepatide alongside GLP-1. Research into GIP agonism has documented:
- Enhanced insulin secretion beyond what GLP-1 alone produces
- Potential effects on fat tissue metabolism and energy expenditure
- Synergistic weight reduction when combined with GLP-1 activation
- Bone density preservation — a notable differentiator from GLP-1 only compounds
The combination of GLP-1 and GIP agonism formed the basis of tirzepatide’s clinical success, and Retatrutide adds a third layer on top.
Glucagon Receptor Agonism
This is what makes Retatrutide unique. Glucagon receptor activation drives:
- Significantly increased energy expenditure — the body burns more calories at rest
- Enhanced breakdown of fat tissue (lipolysis) independent of caloric restriction
- Liver fat reduction, which is relevant to research on non-alcoholic fatty liver disease (NAFLD) — extremely prevalent in the UAE
- Thermogenic effects in adipose tissue
In phase 2 clinical trials, Retatrutide produced greater weight reduction than any previously studied compound in this class — participants in the highest dose group lost an average of 24% of body weight over 48 weeks, surpassing both semaglutide and tirzepatide results in equivalent timeframes.
Retatrutide Research in the Context of the UAE
The metabolic research relevance of Retatrutide in the UAE is significant for several reasons:
Obesity rates: The UAE has one of the highest obesity prevalence rates in the Middle East. Research institutions, clinics and private health organisations in Dubai and Abu Dhabi are actively studying interventions in this area.
NAFLD research: Non-alcoholic fatty liver disease affects a disproportionate number of UAE residents due to dietary patterns and metabolic conditions. Retatrutide’s documented effects on liver fat in research models make it particularly relevant to hepatology researchers in the region.
Diabetes research: The UAE has one of the highest rates of type 2 diabetes in the world. Researchers studying insulin sensitivity, beta cell function and glycaemic control have strong interest in triple agonist mechanisms.
Aesthetic and body composition research: Beyond metabolic disease, there is significant research interest in the Gulf region around body composition — the reduction of adipose tissue while preserving lean muscle mass. Retatrutide’s unique combination of mechanisms is of interest in this context.
Retatrutide vs Semaglutide vs Tirzepatide — What the Research Shows
| Compound | Receptors | Avg Weight Loss (Phase 2/3) | Mechanism |
|---|---|---|---|
| Semaglutide | GLP-1 only | ~15% | Appetite + insulin |
| Tirzepatide | GLP-1 + GIP | ~21% | Appetite + insulin + fat metabolism |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | All of the above + thermogenesis |
Retatrutide represents the current frontier of this research class, and as phase 3 trials progress, demand for research-grade supply in the UAE has increased substantially.
Available Retatrutide Kits at Dxbpeptides
We stock Retatrutide from ZPHC Pharma in the following research kit sizes:
| Kit | Contents |
|---|---|
| 10 MG Kit | ZPHC vials |
| 20 MG Kit | ZPHC vials |
| 40 MG Kit | ZPHC vials |
| 60 MG Kit | ZPHC vials |
| 30 MG Pen Kit | Pre-loaded pen format |
All kits are supplied with refrigeration packaging and carry a Certificate of Analysis. Storage should be maintained at 2-8°C.